Illumina.
American company that develops systems for the analysis of genetic variation
Novacyt H1 Loss Narrows, Revenue Rises 18%
Novacyt’s liquidity manager bought 44,200 shares and sold 44,422 in September, leaving 65,577 shares in treasury; the company has 72.6 million ordinary shares outstanding. For the first half of 2026, revenue rose 18% to £11.56 million and its net loss narrowed to £5.79 million from £6.34 million a year earlier.
Business · 11 sources · 2hRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Illumina
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
Everything about Illumina →- Country
- United States
- Headquarters
- San Diego
- Inception
- 1998
- Website
- https://www.illumina.com/